Drug interactions with other contrast agents and other drugs have not been studied.
Clinical consequences of overdosage with OptiMARK™ Injection have not been reported. Treatment of an overdose is directed toward the support of all vital functions and prompt institution of symptomatic therapy. OptiMARK™ Injection has been shown to be dialyzable (see CLINICAL PHARMACOLOGY).
OptiMARK™ Injection is contraindicated in patients with known allergic or hypersensitivity reactions to gadolinium, versetamide, or any of the inert ingredients.